ASPIrin in Reducing Events in Dialysis ( ASPIRED )
Recruiting
Phase 4
Interventional Study
CKD (Chronic Kidney Disease) Stage 5D
Prior Safety Data
This treatment has already been tested in at least one earlier human trial.
At a Glance
- Age
- 18 and older
- Sex
- Any
- Trial phase
- Phase 4
- Study type
- Interventional
- Purpose
- Treatment
- Participants needed
- 9,000 (estimated)
- Sponsor
- Guangdong Provincial People's Hospital · Other
Think this trial could be right for you?
Answer a few quick questions to see if you may meet the eligibility requirements.
Check Your Eligibility
About This Trial
People with kidney failure requiring dialysis have a much higher risk of developing cardiovascular (CV) disease compared with the general population. A cardiac cause accounts for 58% of all deaths in patients with end stage kidney disease (ESKD). At the same time, this population has increased risks of clotting as well as bleeding episodes. While aspirin is known to reduce cardiovascular complicat…
Trial Locations
Loading…
Loading trial locations…
Eligibility Criteria
Inclusion Criteria:
* Incident or prevalent adults (≥18 years old) dialysis patients are included in the Dialysis Registry.
* Commenced on dialysis with the expectation of ongoing maintenance dialysis requirement.
* Willing and able to provide informed consent for this study.
Exclusion Criteria:
…
Contacts